DWH,

Watch the 9/25/15 webcast and pay attention to the portion by Dr. Kaymar Kalantar-Zadeh. He discusses the signifigance of RVX-208 for kidney disease.

"September 25, 2015: Resverlogix clinical and science teams, along with two members of the international clinical steering committee for the upcoming BETonMACE study, presented a Research and Development Update for RVX-208 "apabetalone" on September 25, 2015 in New York City. Please access the replay here: http://services.choruscall.ca/links/resverlogix150929.html"